Aligned Genetics, Inc.

As of June 30, 2026, Aligned Genetics, Inc. carries a market capitalization of 47.80B, placing it among publicly traded companies globally. Its enterprise value stands at 47.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Aligned Genetics, Inc. has 14.06M shares outstanding.

As of June 30, 2026, Aligned Genetics, Inc. trades at a trailing price-to-earnings ratio of 10.31. The price-to-sales ratio is 2.96, and the price-to-book ratio stands at 1.22.

As of June 30, 2026, Aligned Genetics, Inc. trades at an EV/EBITDA multiple of 14.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.73 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 47.33B versus a market cap of 47.80B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aligned Genetics, Inc. maintains a current ratio of 5.43, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.18, indicating elevated leverage, while an interest coverage ratio of 12.02 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Aligned Genetics, Inc. posted a return on equity (ROE) of 12.56, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 8.92, measuring how efficiently the asset base is converted into earnings. The company generates approximately 247.70M in revenue per employee across its workforce of 65.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.84 indicates how many times Aligned Genetics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Aligned Genetics, Inc. recorded an income tax benefit of -792.64M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 3.85B, leaving 4.64B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Aligned Genetics, Inc.'s stock has declined approximately 21.80% over the past 52 weeks. The 50-day moving average sits at 2,876.70, while the 200-day moving average is 3,596.53.

Over the twelve months ended June 30, 2026, Aligned Genetics, Inc. generated 16.16B in revenue and converted that into 4.64B in net income, yielding earnings per share of 329.89. EBITDA reached 3.22B, while operating income came in at 2.53B.

As of June 30, 2026, Aligned Genetics, Inc. holds 15.44B in cash and equivalents against 14.97B in total debt, resulting in a net debt position of 2.87B. Total book value stands at 39.20B, with working capital of 20.25B providing operational flexibility.

Aligned Genetics, Inc. produced 3.03B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.80B in capital expenditures, free cash flow totaled -9.77B - equivalent to -694.17 per share.

Over the twelve months ended June 30, 2026, Aligned Genetics, Inc. posted a gross margin of 73.52, reflecting its pricing power and cost economics. The operating margin of 15.63 and net profit margin of 28.72 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -20.42: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.68, meaning Aligned Genetics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Aligned Genetics, Inc.'s most recent stock split took place on November 7, 2023 with a 1:2 split ratio.

As of June 30, 2026, Aligned Genetics, Inc. has an Altman Z-Score of 2.41, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.